Polymorphonuclear leukocyte dysfunction syndrome in patients with increasing sepsis severity.
Production of oxygen radicals is required for both microbicidal and tissue-toxic effector functions of granulocytes. Inasmuch as an ambivalent role of polymorphonuclear leukocytes (PMNs) may become apparent during sepsis, we studied levels of hydrogen peroxide (H2O2) production by PMNs depending upon the nature of different particulate and soluble stimuli in patients with increasing sepsis severity. Patients with sepsis (n = 15), severe sepsis (n = 12), or septic shock (n = 33) were prospectively enrolled in the study. Healthy volunteers of comparable age and sex served as controls (n = 50). Unopsonized and opsonized zymosan particles were used to assess adhesion, phagocytosis, and the associated H2O2 production. Zymosan particles are rich in beta-glucans and lectin structures that are known to trigger H2O2 production via two major non-toll-like receptor pathogen recognition receptors, comprising the lectin-binding site in the alpha-chain (CD11b) of the complement receptor type 3 and the more recently identified nonclassical C-type lectin, dectin-1. To determine H2O2 production upon cell activation by soluble stimuli, PMNs were activated by the chemotactic tripeptide (N-formyl-methionyl-leucyl-phenylalanine [fMLP]) alone or after priming of cells by preincubation with tumor necrosis factor alpha. To get insight into the changes of fMLP receptor classical intracellular signaling pathways, PMNs were also incubated with the calcium ionophore A23187 and the phorbol ester phorbol myristate acetate, bypassing receptor-dependent signal transduction to directly activate calcium/calmodulin kinase- and protein kinase C-dependent pathways, respectively. As compared with healthy volunteers, levels of H2O2 production by PMNs from septic patients varied depending upon the nature of the activating signal: reduced (zymosan), unchanged (phorbol myristate acetate, opsonized zymosan), and enhanced (spontaneous, fMLP, fMLP + tumor necrosis factor alpha, A23187), with the changes most pronounced in patients with septic shock. Specifically, phagocytosis of zymosan and the associated H2O2 production were significantly decreased whereas spontaneous and stimulated H2O2 production elicited by soluble stimuli strongly increased. Thus, these findings suggest the development of a PMN dysfunction syndrome in patients with increasing sepsis severity. Moreover, as binding of zymosan particles to the PMNs' surface remained unchanged despite increasingly suppressed phagocytosis and associated H2O2 production, observed effects are likely to reflect defects in signaling by the lectin-binding site of CD11b and/or the beta-glucan receptor dectin-1, respectively.
Kaufmann
Ines
I
Department of Anaesthesiology, Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany.
Hoelzl
Alwin
A
Schliephake
Florian
F
Hummel
Theresia
T
Chouker
Alexander
A
Peter
Klaus
K
Thiel
Manfred
M
D002097:C-Reactive Protein / Q000032:analysis; D018821:CD18 Antigens / Q000378:metabolism; D000001:Calcimycin / Q000494:pharmacology; D002116:Calcitonin / Q000097:blood; D006801:Humans; D006861:Hydrogen Peroxide / Q000378:metabolism; D015850:Interleukin-6 / Q000097:blood; D007958:Leukocyte Count; D008875:Middle Aged; D009102:Multiple Organ Failure / Q000097:blood / Q000175:diagnosis / Q000503:physiopathology; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D018375:Neutrophil Activation / Q000187:drug effects / Q000502:physiology*; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D009895:Opsonin Proteins / Q000378:metabolism; D010587:Phagocytosis / Q000187:drug effects / Q000502:physiology; D011498:Protein Precursors / Q000097:blood; D018805:Sepsis / Q000097:blood / Q000378:metabolism / Q000503:physiopathology*; D012720:Severity of Illness Index; D012772:Shock, Septic / Q000097:blood / Q000378:metabolism / Q000503:physiopathology; D013577:Syndrome; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D015054:Zymosan / Q000378:metabolism
D018821:CD18 Antigens; D015850:Interleukin-6; D009895:Opsonin Proteins; D011498:Protein Precursors; D014409:Tumor Necrosis Factor-alpha; D000001:Calcimycin; D009240:N-Formylmethionine Leucyl-Phenylalanine; D002116:Calcitonin; D002097:C-Reactive Protein; D015054:Zymosan; D006861:Hydrogen Peroxide; D013755:Tetradecanoylphorbol Acetate